安杰思股价跌1.08%，华泰保兴基金旗下1只基金重仓，持有3640股浮亏损失2329.6元

Group 1 - The core viewpoint of the news is that Anjisi's stock price has decreased by 1.08% to 58.59 CNY per share, with a total market capitalization of 4.753 billion CNY as of the report date [1] - Anjisi Medical Technology Co., Ltd. specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, with its main business revenue composition being: GI category 62.74%, EMR/ESD category 23.26%, ERCP category 11.04%, instruments category 2.21%, and others 0.74% [1] Group 2 - Huatai Baoxing Fund holds a significant position in Anjisi, with the Huatai Baoxing Health Consumption A fund owning 3,640 shares, representing 6.03% of the fund's net value, making it the sixth-largest holding [2] - The Huatai Baoxing Health Consumption A fund has experienced a loss of 14.34% this year, ranking 8,076 out of 8,085 in its category, and a loss of 15.05% over the past year, also ranking 8,073 out of 8,085 [2] - The fund manager, Zhao Xuzhao, has been in position for 7 years and 353 days, with the fund's total asset size at 653 million CNY and a best return of 45.34% during his tenure [2]